A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a ...

Americans are split on using weight loss drugs such as Ozempic and Wegovy to treat obesity or weight-related conditions, ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

Childhood obesity continues to be a growing problem in out country. So, should the government regulate food advertising like it did with cigarettes?

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

President Donald Trump has nominated Kennedy to be the secretary of the U.S. Department of Health and Human Services, which ...

T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

Few drugs have generated as much excitement as Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy. In June 2021, Novo Nordisk won ...

That locked up the obesity drug. But after 9 Meters started ... Wegovy, for example, "doesn't really work" — at least to the Food and Drug Administration standard of weight loss of 5% or more ...

The US Food and Drug Administration approved the first GLP-1 in 2005, for treatment of type 2 diabetes. In the past few years, the agency has approved several GLP-1s for obesity after patients ...